Close Menu

BioFortis

Gentris has selected BioFortis' Labmatrix and Qiagram software to manage samples and data collection and integration activities in its biorepository.

NEW YORK (GenomeWeb News) – The French government has provided €13.4 million ($17.4 million) to fund the Innovative MODels Initiative (IMODI), a partnership aimed at facilitating the development of new cancer treatments.

OpenEye has released AFITT 2.2.0, an application designed to help crystallographers fit ligands to observed data.

BioFortis said the foundation will use the platform to collect and manage patient specimen data and clinical information, track shipment status, analyze data from thousands of patient biospecimens, and view real-time study results from pre-built or ad hoc data queries.

Investigators at Rush University Medical Center will use BioFortis' Labmatrix to manage its biobank and biomarker data for research efforts focused on early detection and diagnosis of cancer and neurodegenerative diseases.

BioInform's Licensing Roundup: July and August's Software Deals

The software will be used to develop workflow-driven protocols to support specimen biobanking, biomarker discovery, and translational research.

The Guardian reports that some UK physicians are calling for increased regulation of direct-to-consumer genetic tests.

US tax agency says 23andMe's genetic health test can be claimed as a medical expense for tax purposes, the Wall Street Journal reports.

Two Democratic lawmakers argue at USA Today that independent science is under attack by the Trump Administration.

In PLOS this week: networks of genes co-expressed in depression, role of minichromosome maintenance genes in lung adenocarcinoma, and more.